Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 1
2005 1
2011 2
2015 2
2016 1
2017 2
2018 2
2019 3
2020 4
2021 2
2022 1
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
Ma Y, Qi Y, Zhou Z, Yan Y, Chang J, Zhu X, Han J, Wu H, Tao Y, Fan F. Ma Y, et al. Phytomedicine. 2024 Jan;122:155171. doi: 10.1016/j.phymed.2023.155171. Epub 2023 Oct 31. Phytomedicine. 2024. PMID: 37925891
In clinical practice, the amalgamation of traditional Chinese medicine with other treatment modalities has exhibited noteworthy efficacy in managing disease progression and enhancing quality of life. OBJECTIVE: To substantiate the regulatory effects of Shenqi Fuzheng Injec …
In clinical practice, the amalgamation of traditional Chinese medicine with other treatment modalities has exhibited noteworthy efficacy in …
Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer.
Yan B, Shi R, Lu YY, Fang DD, Ye MN, Zhou QM. Yan B, et al. PLoS One. 2023 Jan 24;18(1):e0279752. doi: 10.1371/journal.pone.0279752. eCollection 2023. PLoS One. 2023. PMID: 36693064 Free PMC article.
BACKGROUND: Shenqi Fuzheng injection (SQFZ) combined with chemotherapy can sensitize tumour cells. ...
BACKGROUND: Shenqi Fuzheng injection (SQFZ) combined with chemotherapy can sensitize tumour cells. ...
Efficacy and safety of traditional Chinese medicines combined with conventional Western medicines in the treatment of type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.
Ma K, Zhou L, Zhang Y, Zhao J, Yao C, Tian C, Li M. Ma K, et al. Front Endocrinol (Lausanne). 2023 May 8;14:1134297. doi: 10.3389/fendo.2023.1134297. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37223050 Free PMC article.
Stata 15 and RevMan 5.4 software were used to conduct a network meta-analysis and a traditional meta-analysis. RESULTS: The results showed that shenqi jiangtang granule combined with sulfonylurea, shenqi jiangtang granules combined with metformin and jinlida granule …
Stata 15 and RevMan 5.4 software were used to conduct a network meta-analysis and a traditional meta-analysis. RESULTS: The results showed t …
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
Gao H, Duan Y, Fu X, Xie H, Liu Y, Yuan H, Zhou M, Xie C. Gao H, et al. PLoS One. 2018 Dec 6;13(12):e0207683. doi: 10.1371/journal.pone.0207683. eCollection 2018. PLoS One. 2018. PMID: 30521536 Free PMC article.
In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. ...
In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic …
A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis.
Zhu J, Liu L, Zhu Z, Yang Z, Hu J, Ding F, Zhou Y, Su X, Ge J, Liu X, Tang L, He Y, Zhou G, Ji Z, Li Y, Pang W, Zhang R. Zhu J, et al. Coron Artery Dis. 2021 Sep 1;32(6):526-533. doi: 10.1097/MCA.0000000000000994. Coron Artery Dis. 2021. PMID: 33229940 Clinical Trial.
RESULTS: At 9-month follow-up, the in-segment late loss was 0.29 0.43 mm with Shenqi versus 0.30 0.46 mm with SeQuent Please, and the one-sided 97.5% upper confidence limit of the difference was 0.14 mm, achieving noninferiority of Shenqi compared with SeQuent Pleas …
RESULTS: At 9-month follow-up, the in-segment late loss was 0.29 0.43 mm with Shenqi versus 0.30 0.46 mm with SeQuent Please, and the …
Effect of Shenqi Yangxin decoction on high mobility group box 1 and inflammatory signal pathway in a rat model of dilated cardiomyopathy.
Shen L, Xing Q, Lu S, Zhou Y, Zhou C, Li L. Shen L, et al. J Tradit Chin Med. 2018 Dec;38(6):862-871. J Tradit Chin Med. 2018. PMID: 32186133 Free article.
OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction (SQYXD) on heart function in a rat model of dilated cardiomyopathy (DCM) and its potential mechanisms. ...SQYXD inhibited the upregulation of HMGB1 expression and its downstream inflammatory factors. CONCLUS …
OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction (SQYXD) on heart function in a rat model of dilated cardiomyopathy …
Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison.
Ludwig S, Conradi L, Cohen DJ, Coisne A, Scotti A, Abraham WT, Ben Ali W, Zhou Z, Li Y, Kar S, Duncan A, Lim DS, Adamo M, Redfors B, Muller DWM, Webb JG, Petronio AS, Ruge H, Nickenig G, Sondergaard L, Adam M, Regazzoli D, Garatti A, Schmidt T, Andreas M, Dahle G, Walther T, Kempfert J, Tang GHL, Redwood S, Taramasso M, Praz F, Fam N, Dumonteil N, Obadia JF, von Bardeleben RS, Rudolph TK, Reardon MJ, Metra M, Denti P, Mack MJ, Hausleiter J, Asch FM, Latib A, Lindenfeld J, Modine T, Stone GW, Granada JF; CHOICE-MI and the COAPT Trial Investigators. Ludwig S, et al. Circ Cardiovasc Interv. 2023 Jun;16(6):e013045. doi: 10.1161/CIRCINTERVENTIONS.123.013045. Epub 2023 May 16. Circ Cardiovasc Interv. 2023. PMID: 37194288 Free article.
Preliminary Study of the Distinctive Mechanism of Shenqi Compound in Treating Rats with Type 2 Diabetes Mellitus by Comparing with Metformin.
Fu X, Zhou X, Liu Y, Lei Y, Xie H, Leng Y, Gao H, Xie C. Fu X, et al. Curr Vasc Pharmacol. 2023;21(2):120-127. doi: 10.2174/1570161121666230208130349. Curr Vasc Pharmacol. 2023. PMID: 36752289
BACKGROUND: In China, traditional Chinese medicine (TCM) has been used to treat type 2 diabetes mellitus (T2DM) for centuries. METHODS: To investigate how the TCM ShenQi (SQC) formulation differs from metformin, four rat groups, including control, model, T2DM rats treated …
BACKGROUND: In China, traditional Chinese medicine (TCM) has been used to treat type 2 diabetes mellitus (T2DM) for centuries. METHODS: To i …
The Anti-Allergic Rhinitis Effect of Traditional Chinese Medicine of Shenqi by Regulating Mast Cell Degranulation and Th1/Th2 Cytokine Balance.
Shao YY, Zhou YM, Hu M, Li JZ, Chen CJ, Wang YJ, Shi XY, Wang WJ, Zhang TT. Shao YY, et al. Molecules. 2017 Mar 22;22(3):504. doi: 10.3390/molecules22030504. Molecules. 2017. PMID: 28327534 Free PMC article.
Shenqi is a traditional Chinese polyherbal medicine has been widely used for the treatment of allergic rhinitis (AR). The aim of this study was to investigate the anti-allergic rhinitis activity of Shenqi and explore its underlying molecular mechanism. Ovalbumin (OV …
Shenqi is a traditional Chinese polyherbal medicine has been widely used for the treatment of allergic rhinitis (AR). The aim of this …
33 results